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ABSTRACT  
In a previous in vitro study, we have shown that the kernel oil of fruits of the tree 
Balanites aegyptiaca referred to as Balanites kernel oil ((BKO) is active against 
dermatophytes (i.e. superficial mycosis, ringworms, tineas (T. captitis, T. 
cercinata and T. pedis). We report here our clinical trials with BKO. Trials were 
performed on patients presenting at Wad Medani Dermatology Teaching Hospital 
as well as primary school children in Elsoreeba Town (5 km south of Wad 
Medani). Not all patients followed treatment till completely cured. Patients treated 
with BKO (half of the total) achieved complete cure in 3-5 weeks, on average, 
while those treated with the standard antifungal drug Miconazole (half of the total 
patients) did the same in the longer period of 3-8 weeks. Photographs showing 
progress of response to BKO treatments are included. BKO has great potential for 
development as a commercial drug for the treatment of dermatophytes.  
  
INTRODUCTION  
Dermatophytes are superficial fungal infections which affect the outer layer of the 
skin, the nail and the hair. They are fungi that require keratin for growth and they 
spread by direct contact from other people (anthropophilic), animals (zoophilic) 
or soil (geophilic organisms). Many species of these infectuous fungi, recognized 
by the nature of macro conidia (asexual spores), belong to the three genera, 
Trichophyton, Microsporum and Epidermophyton (Rook et al. 1988) (1). Species 
of Trichophyton affect the skin, hair and nail, those of Microsporum affect the 
skin and hair while species of Epidermophyton affect the skin and nail. There are 
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many species; their spores can live for more than a year in human skin scales in 
the environment. Dermatophtes are referred to as "tinea" infections and they are 
also named after the body site involved (Hunter, 1995) (2). Skin diseases are 
widespread in different areas of Sudan and the history of dermatology in Sudan 
has been reviewed by Ahmed (2004) (3). The most widely spread superfical 
mycoses causing species in Sudan are Trichophyton soudanense, T. rubrum, T. 
schoenleinii, T. violaceum and T. audouinii. The major diseases are Tinea capitis, 
Tinea pedis, Tinea corporis, Tinea ungum and Tinea cruris. Tinea capitis is 
especially prevalent among school children and it is characterized by irregular 
alopecia and scaling. Generally Tinea capitis can be identified by the presence of 
branching hyphae and spores on potassium hydroxide (KOH) microscopy, but if 
spores or hyphae are not visualized, cultures of samples from, affected areas can 
be used to detect specific disease-causing fungi. Also, wood’s lamp may help 
detection of certain species through its fluorescence (Hainer, 2003) (4).  
The major cause of Tinea capitis today is Trichophyton tonsurans (AbdelRahman, 
1997 (5) ,  Aly, 1999)(6) ,  Table 1 shows the topical therapy used to treat superficial 
mycoses (Evans et al., 1997 (7)  . Friedlander, 2000)  (8) . Only the major chemical 
groups of drug’s are mentioned.  
  
  
Table 1: Current topical therapy for dermatophytes infection  
  
Agent groups  Formulation  Frequency of application  
Allyamines  1% cream, gel or solution  Once or twice daily  
Benzylamines  1% cream  Once or twice daily  
Imidazoles  1% cream, solution or lotion  
1% shampoo  
2% cream, spray, powder  
Twice daily  
Once daily  
Twice daily  
  
Balanites kernels, roasted and pounded, are traditionally used in a few areas in 
Western Sudan, according to Sudanese folk medicinal beliefs, to treat a variety of 
skin disease (Osman, 2001) (9). Our previous in vitro work (Osman et al., 2006) 
(10) has pointed to the great prospect of the oil of Balanites agyptiaca as a potential 
antifungal agent against Miccrosporum audouinii, Trichophyton soudanense and 
T. mentagrophytes causing the diseases mentioned above. We report here our 
findings on clinical trails performed with this oil.  
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Specific objectives of this study included determining the effective dose and to 
extend our in vitro work on BKO to clinical trails. A major impact of this work, 
if Balanites oil proved to be an effective antifungal agent, at the clinical level, is 
reduction of treatment cost. A well formulated Balanites oil-based drug may find 
international demand.   
  
MATERIALS AND METHODS  
Preparation of Balanites oil:  
All solvents used were of standard analytical grade. The oil was prepared from 
the separated fruit kernel (Fig. 1) by Soxhlet extraction using hexane according to 
the American Oil Chemists Society (AOCS) methods (1973) (11). The solvent was 
completely removed in a rotary evaporator. The crude dried oil was packed in 20 
ml screw-capped ampoules for dispensing to patients.  
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EDITORIAL  
 
Gezira Journal Of Health Sciences vol.2(1) 2006  
 
Gezira Journal Of Health Sciences vol.2(1) 2006 
 
                 
  
  
Fig. 1 (a & b):  The Balanites fruit (Laloab) and its parts.  
Clinical test  
Our targets were patients presenting to Wad Medani Dermatology Teaching 
Hospital, referred from rural hospitals and health Centres. They were of different 
age groups of both sexes. Also targeted were pupils (girls and boys) of Elsoreeba 
Primary School. The school, 5 km south of Wad Medani, was regularly visited. 
In-form consent was obtained from all selected patients before their entry in this 
study (Fig. 2). The diagnosis of each patient was done first clinically and then 
confirmed by the University of Gezira Medical Laboratory, Wad Medani, Sudan, 
before starting medical treatment. The diagnostic test involved taking scrapings 
from the edges of affected areas, adding potassium hydroxide and examining 
microscopically for spores and hyphae. All patients were photographed before, 
during and after treatment which was done once a week till complete cure was 
achieved. The latter was confirmed by laboratory findings. Each patient had a 
follow-up form (Fig. 2). All of the case group pateints received either BKO or 
Miconazole therapy, the standard anti-fungal drug (pateints were initially 
assigned to either the test or control group by random selection. Thereafter, the 
patient remained in the group assigned)  
  
  
  
( b )  
K e r n e l 
  
W h o l e  f r u i t s  
E p i c a r p  +  M e s o c a r p  
W o o d y  p a r t  
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.   
Fig. 2 : Sample form used for patient’s data and signature (consent)  
  
RESULTS AND DISCUSSION  
  
Table 2 shows the overall breakdown of patients involved in this study. Eightyfive 
patients started the treatment (BKO or Miconazole-Mic-), thirty-four of them 
discontinued treatment after two weeks because of long distance, transport 
problems and socioeconomic reasons. Nineteen patients showed considerable 
improvement after 2-4 weeks of treatment. However, presumably for the same 
reasons, they discontinued treatment (Fig. 4). Thirty-two patients continued the 
treatment to the end, i.e. till totally cured (Fig. 3), sixteen of them were under 
BKO treatment and the other sixteen received Miconazole. All patients (case and 
control groups) affected by Tinea capitis showed the presence of branching 
hyphae and spores under laboratory examination (KOH microscopy). Complete 
cure, at the end of treatment, was similarly confirmed.   
The shorter time for complete cure was observed in patients treated with BKO (25 
weeks), whereas those treated with Miconazole took a longer period of time (3-8 
weeks).  
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           Table 2: Breakdown of patients of the study: their numbers, diagnosis, treatment 
received and their cure rates (Mic=Miconazole).  
  
Type of  
patients  
Number of 
patients  
 Diagnosis  Comments on  
response to 
treatment  
Case 
(BKO)  
Control  
(Mic)  
Clinical   Laboratory  
(hyphae & spores)  
Group 1  18  16  +ve  +ve  Patients received 
one  or two 
treatments (1-2 
weeks)  but did not 
show up again   
Group 2  8  11  +ve  +ve  Patients markedly 
improved  but 
discontinued  
treatment (2-4 
weeks)  
Group 3  16  -  +ve  +ve  Continued 
treatment till totally 
cured,  in 2-5 weeks  
Group 4  -  16  +ve  +ve  Continued  
treamtment   
till totally cured,  
in 3-8 weeks  
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Fig. 3a:  Case no.1, Age: 5 years, Diagnosis: T. capitis, Treatment duration: 3 weeks  
 
  
Fig. 3b: Case No.2, Age: 11 years, Diagnosis: T. capitis, Treatment duration:5 weeks  
 
Fig. 3c: Case No.3, Age: 19 years, Diagnosis: T. capitis, Treatment duration: 5 weeks   
 
  
Fig.3d: Case No:  4, Age: one year, Diagnosis: T. circinata, Treatment duration:4 weeks  
 
Fig. 3e: Case No:  5, Age: 14 years, Diagnosis: T. capitis, Treatment duration: 5 weeks  
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  Fig. 3 f: Case no.6, Age: 8 year, Diagnosis: T. capitis, Treatment duration: 2 weeks  
  
Fig. 3(a-f): Photographs of patients showing progress of treatment with BKO till 
complete cure (Group 3, in Table 2). Inserted numbers refer to the progress of 
treatment, in weeks. The last picture   (photograph) in each case represents the 
state diagnosed as completely cured (Note that hair regrowth had just started in    
Fig. 3b and 3 c, at the end of BKO treatment).  
Fig. 3 shows pthotographs of selected patients who continued treatment with BKO 
till completely cured (Group 3, Table 2). Fig. 4 contains photographs of some of 
Group 2 (Table 2) patients, i.e., those who markedly improved but discontinued 
treatment.  
Hainer (2003) (4) reported on the difficulties of the therapeutic treatment of Tinea 
capitis. According to this author topical treatment is not effective and there is a 
need for a systemic antifungal agent that is able to penetrate the hair follicles. 
Moreover, with resistant organisms, treatment must be continued for 6 to 12 
weeks. Griseofulvin was the only agent labeled for the treatment of Tinea capitis 
by the U.S. Food and Drug Adminstration at that time (Elewski, 2000 (12)  . Hainer, 
2003) (4) . In our study T. capitis was completely cured with externally applied 
BKO, without the need for a systemic drug.   
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    Fig. 4 a: Case No 1:  Age: 6 year, Diagnosis: T. circinata, Treatment duration: 3 weeks  
  
 
 
  
    Fig. 4 b: Case No 3:  Age: 5 year, Diagnosis: T. capitis, Treatment duration: 2 weeks  
  
 
  
  Fig. 4 (a-c): Photographs of patients who markedly improved with   BKO but       
discontinued treatment (group 2, in Table 2).  
The cost of Miconazole therapy treatment is currently estimated at 2000 S.D. per 
week (treatment up to 8 weeks), totalling up to 16000 S.D. for the full cost of 
treatment. On the other hand, we estimate that the total cost of BKO treatment is 
below 500 S.D. Moreover decreasing treatment duration has the economic impact 
of time saving.  
Our research is continuing on to determine the exact nature of the active 
ingredient, its stability, the effective dose and other research work needed so as to 
proceed to the next stage of drug formulation. A properly formulated drug may 
find regional or international markets.  
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